Natasha Setia, MD

Title(s)CLINICAL INSTRUCTOR, Medicine
SchoolSchool of Medicine
Address521 Parnassus Avenue
San Francisco CA 94117
Phone--
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma. J Hematol Oncol. 2021 08 17; 14(1):126. Martinez-Lopez J, Alonso R, Wong SW, Rios R, Shah N, Ruiz-Heredia Y, Sanchez-Pina JM, Sanchez R, Bahri N, Zamanillo I, Poza M, Buenache N, Encinas C, Juarez L, Miras F, Collado L, Barrio S, Martin T, Cedena MT, Wolf J. PMID: 34404440; PMCID: PMC8369640.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    2. The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements. PLoS One. 2020; 15(8):e0237155. Cedena MT, Martin-Clavero E, Wong S, Shah N, Bahri N, Alonso R, Barcenas C, Valeri A, Salazar Tabares J, Sanchez-Pina J, Cuellar C, Martin T, Wolf J, Lahuerta JJ, Martinez-Lopez J. PMID: 32866200; PMCID: PMC7458342.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    3. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 2020 07 28; 4(14):3295-3301. Martinez-Lopez J, Wong SW, Shah N, Bahri N, Zhou K, Sheng Y, Huang CY, Martin T, Wolf J. PMID: 32706892; PMCID: PMC7391154.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    4. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. Blood Adv. 2020 05 26; 4(10):2163-2171. Alonso R, Cedena MT, Wong S, Shah N, Ríos-Tamayo R, Moraleda JM, López-Jiménez J, García C, Bahri N, Valeri A, Sánchez R, Collado-Yurrita L, Martin T, Wolf J, Lahuerta JJ, Martínez-López J. PMID: 32433744; PMCID: PMC7252556.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    5. Risk factors for multiple epinephrine doses in food-triggered anaphylaxis in children. Ann Allergy Asthma Immunol. 2018 10; 121(4):469-473. Tsuang A, Menon NR, Bahri N, Geyman LS, Nowak-Wegrzyn A. PMID: 29940309.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    Natasha's Networks
    Concepts (36)
    Derived automatically from this person's publications.
    _
    Co-Authors (2)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _